





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : G01N 33/48, C09B 23/08, 23/06 C09B 23/04, 23/00, G01N 33/52 G01N 33/58	A1	(11) International Publication Number: WO 93/06482 (43) International Publication Date: 1 April 1993 (01.04.93)
(21) International Application Number: PCT/US92/07867 (22) International Filing Date: 16 September 1992 (16.09.92) (30) Priority data: 761,177 16 September 1991 (16.09.91) US (71) Applicant: MOLECULAR PROBES, INC. [US/US]; 4849 Pitchford Avenue, Eugene, OR 97402-9144 (US). (72) Inventors: YUE, Stephen, T. ; 3746 Plumtree Drive, Eu- gene, OR 97402 (US). JOHNSON, Iain, D. ; P.O. Box 168, Springfield, OR 97477 (US). HAUGLAND, Ri- chard, P. ; 2233 Lasater, Eugene, OR 97405 (US). (74) Agents: HELFENSTEIN, Allegra, J.; Molecular Probes, Inc., 4849 Pitchford Avenue, Eugene, OR 97402-9144 (US) et al.		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE). Published With international search report.

(54) Title: DIMERS OF UNSYMMETRICAL CYANINE DYES



(57) Abstract

The invention relates to dimers of unsymmetrical cyanine dyes, typically dimers of benzthiazole or benzoxazole derivatives, that exhibit enhanced fluorescence on binding with DNA or RNA. The dimers generally have formula (1), where R¹ and R², which may be the same or different, are alkyl groups having 1-6 carbons; X is O, S, or N-R³, where R³ is H or an alkyl group having 1-6 carbons; Z is O, S, or N-R⁴, where R⁴ is H or an alkyl group having 1-6 carbons; n and s, which may be the same or different, = 0, 1, or 2; Y is HC=CH; and p, m, q, and r = 0 or 1, such that p + m = 1 and q + r = 1; and where -BRIDGE- has general formula (2), where α, β, γ, and δ, which may be the same or different, are integers greater than 1 and less than 5; I and II, which may be the same or different, = 0 or 1; and A¹, A², and A³, which may be the same or different, are independently O; S; (CH₂)_μ where μ = 0 or 1; -(NR⁵)- where R⁵ is H or an alkyl group having 1-6 carbons; or -(N+R⁶R⁷)- where R⁶ and R⁷, which may be the same or different, are independently hydrogen or an alkyl group having 1-6 carbons.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO	Norway
BG	Bulgaria	GR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	PT	Portugal
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovak Republic
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CS	Czechoslovakia	LU	Luxembourg	SU	Soviet Union
CZ	Czech Republic	MC	Monaco	TD	Chad
DE	Germany	MG	Madagascar	TG	Togo
DK	Denmark	ML	Mali	UA	Ukraine
ES	Spain			US	United States of America

DIMERS OF UNSYMMETRICAL CYANINE DYES

FIELD OF THE INVENTION

- 5 The invention relates to novel fluorescent dyes. In particular, the invention relates to dimers of unsymmetrical cyanine dyes used for nucleic acid staining.

BACKGROUND OF THE INVENTION

- Fluorescent dyes have many uses and are known to be particularly suitable for
10 biological applications in which the high detectability of fluorescence is desirable. By binding to a specific biological ingredient in a sample, a fluorescent dye can be used to indicate the presence or the quantity of the specific ingredient in a sample. A variety of fluorescent dyes are available for specific fluorescent staining and quantitation of DNA and RNA, and other applications involving nucleic acids.

- 15 Unsymmetrical cyanine dyes were described long before much was known about DNA by Brooker, et al., J. AM. CHEM. SOC. 64, 199 (1942). These dyes have since been found to be useful in fluorescent staining of DNA and RNA. The dye sold under the tradename Thiazole Orange has particular advantages in the quantitative analysis of immature blood cells or reticulocytes. U.S. Patent No. 4,883,867 to Lee, et al. (1989)
20 ('867 patent); Lee, et al., Thiazole Orange: A New Dye for Reticulocyte Analysis, CYTOMETRY 7, 508 (1986). As indicated in the '867 patent to Lee, et al., the dye used for this purpose must be able to penetrate the cell membrane.

- The inventors have discovered that a composition that includes two suitably connected unsymmetrical cyanine dye units, i.e. a cyanine dye dimer, is a polar compound
25 that is unable to readily penetrate cell membranes. Nevertheless, the composition discovered by inventors is highly useful as a stain for nucleic acids because it is sensitive to even small fragments of nucleic acid polymers not contained inside living cells, e.g. in cell extracts, as well as to nucleic acids in permeabilized cells. The dimer is neither anticipated nor obvious in view of Thiazole Orange or related compounds that are monomers.

- 30 Other dimer compounds that are known to bind to nucleic acids with a large fluorescence enhancement include variants of ethidium homodimer, acridine homodimers, acridine-ethidium heterodimer, and 7-hydropyridocarbazoles, see, e.g., Rye, et al., NUCLEIC ACIDS RESEARCH 19(2), 327 (1990); Haugland, MOLECULAR PROBES
HANDBOOK OF FLUORESCENT PROBES AND RESEARCH CHEMICALS Set 28
35 (1989). Although the Rye, et al. reference mentions characteristics that influence the affinity and mode of binding dimers to DNA, the reference does not describe the compounds

used in this invention. The novel dimer compounds described herein are not only different in structure from other dimer compounds but are also superior to other dimers and to Thiazole Orange in their sensitivity to nucleic acids.

5 DESCRIPTION OF DRAWINGS

Figure 1. Synthesis Pathway of a Representative Dimer from Intermediates

A representative dimer is synthesized according to the procedure described in Examples 1 or 2. Where X is S, the compound is a dimer of a benzthiazole derivative.

10 Where X is O, the compound is a dimer of a benzoxazole derivative.

Figure 2. Absorption Spectra of Representative Compounds

A. Absorption spectra of a representative benzthiazole derivative dimer (Compound 1) (4x10⁻⁶ M) in 10 mM Tris, 1 mM EDTA, 2 M NaCl, pH 7.4 with addition of calf thymus DNA (Sigma Chem. Co. D-1501, Lot 118F-9525).

DNA additions are: 1) none; 2) 11 µg/ml 3) 25 µg/ml and 4) 32 µg/ml.

DNA concentrations are based on A₂₆₀=1.0 for 50 µg/ml DNA [Ausubel et al., SHORT PROTOCOLS IN MOLECULAR BIOLOGY, pp 359, John Wiley and Sons].

20

B. Absorption spectra of a representative benzoxazole derivative dimer (Compound 2) (4x10⁻⁶ M) in 10 mM Tris, 1 mM EDTA, 2 M NaCl, pH 7.4 with addition of calf thymus DNA (Sigma Chem. Co. D-1501, as Figure 1).

DNA additions are: 1) none; 2) 11 µg/ml 3) 25 µg/ml and 4) 32 µg/ml as in Figure 1.

25

Figure 3. Fluorescence Spectra of Representative Compounds

A. Fluorescence spectra of a representative benzthiazole derivative dimer (Compound 1) (1.0 µM) in 10 mM Tris, 1 mM EDTA, 2.0 M NaCl, pH 7.4, showing effect of addition of DNA and RNA. Nucleic acid concentrations were: DNA (Calf Thymus DNA, Sigma Chemical Co. Product D-1501) = 15.4 µg/ml and RNA (Calf Liver RNA, Sigma Chemical Co. Product R-7250) = 18.6 µg/ml. Nucleic acid concentrations were calculated on the basis of A_{260 nm} = 1.0 = 50 µg/ml double stranded DNA or 40 µg/ml single stranded RNA. Fluorescence spectra were recorded on an SLM Instruments SPF 500C spectrofluorometer with excitation at 450 nm. Fluorescence maximum in presence of DNA or RNA is 533 nm (+/- 1 nm). Essentially similar nucleic acid induced fluorescence enhancement was observed

35

(data not shown) in a low salt (50 mM NaCl) buffer with the exception that the weak long wavelength emission (maximum 645 nm) of the free dye was absent.

- B. Effect of DNA and RNA on fluorescence spectra of a representative benzoxazole derivative dimer (Compound 2). All experimental conditions are the same as those used in the experiment shown in Figure 3A. Fluorescence maximum in the presence of DNA or RNA is 509 nm (+/- 1 nm).

Figure 4. Titration of DNA.


10

DNA titrations of a representative benzthiazole derivative dimer (Compound 1) (\square) and a representative benzoxazole derivative dimer (Compound 2) (\circ) in 10 mM Tris, 1 mM EDTA, 50 mM NaCl pH 7.4. The procedure of Example 6 is followed. All data points represent averages of duplicate determinations from which a blank reading for the same concentration of dye in the absence of DNA has been subtracted. The lowest detectable level of DNA in these measurements is 0.01 $\mu\text{g/ml}$ which corresponds to 2 ng of DNA in the 200 μl analytical volume.

15

20 SUMMARY OF THE INVENTION AND DESCRIPTION OF PREFERRED EMBODIMENTS

The dyes used for the invention are dimers of unsymmetrical cyanine dye units. The dye units are linked by a bridge between the cyanine dye units. The two dye units, which may be the same or different, may be bridged symmetrically or asymmetrically. The novel dimers generally have the formula:



R^1 and R^2 , which may be the same or different, are alkyl groups having 1-6 carbons. Preferably R^1 and R^2 have 1-3 carbons.

35

X is O, S, or N- R^3 , where R^3 is H or an alkyl group having 1-6 carbons. Z, which

may be the same as X or different, is O, S, or N-R⁴, where R⁴ is H or an alkyl group having 1-6 carbons. Preferably, X and Z are O or S. One embodiment of the invention is a dimer of benzoxazole analogs, where both X and Z are oxygen. Another embodiment of the invention is a dimer of benzthiazole analogs where both X and Z are sulfur.

5

The subscripts n and s, which determine the length of each dye unit, = 0, 1, or 2. The dye units that form the dimer may be the same length or different. Changing the length of the dye units by increasing n or s or both will affect the spectral properties of the dye units and of the dimer.

10

Y is HC=CH, the position of which is indicated by the subscripts p, m, q, and r, which = 0 or 1. When p = 1, m = 0 and vice versa. When q = 1, r = 0, and vice versa. When p and q equal 1, and n and s equal 0, and X and Z are sulfur, the compound is a dimeric analog of Thiazole Orange.


15

The BRIDGE linking the two dye units, which may be the same or different, is an aliphatic chain containing a backbone of 4-19 carbon atoms. The carbon backbone may be interspersed at one or more intervals with a non-carbon backbone atom ("heteroatom"). The heteroatoms, which may be the same or different are N, O, or S. Nitrogen is the preferred heteroatom. The nitrogen heteroatom may be substituted with one or more alkyl substituents having 1-6 carbon atoms, which alkyl substituents may be the same or different.

20

BRIDGE has the general formula:

25



30

The subscripts α , β , γ , and δ , which may be the same or different, indicate the size of the alkyl units, which contain from 2-4 carbon atoms each. The subscripts I and II, which may be the same or different, = 0 or 1, indicating the presence or absence of that unit.

35

A¹, A², and A³ may be the same or different. A¹ is an additional alkyl group (CH₂) _{μ} , where μ = 0 or 1. Alternatively, A¹ is a heteroatom O or S, or a substituted or unsubstituted nitrogen heteroatom -(NR⁵)- where R⁵ is H or an alkyl group having 1-6 carbons, or -(N⁺R⁶R⁷)- where R⁶ and R⁷, which may be the same or different, are independently hydrogen or an alkyl group having 1-6 carbons. Likewise, A² and A³, which

may be the same as or different from A^1 and each other, are independently $(CH_2)_\mu$ where $\mu = 0$ or 1; O; S; $-(NR^5)-$ where R^5 is H or an alkyl group having 1-6 carbons; or $-(N^+R^6R^7)-$ where R^6 and R^7 , which may be the same or different, are independently hydrogen or an alkyl group having 1-6 carbons. In a preferred embodiment, A^1 and A^3 are present as -

5 $(N^+R^6R^7)-$. More preferably, R^6 and R^7 are methyl groups and $II = 0$, eliminating the presence of A^2 .

The spectral properties of the novel dimer compounds are similar to but different from those of known cyanine dyes. The novel dimer dyes (unbound) exhibit a strong

10 absorption peak in the range of from about 400 nm to about 550 nm, however the dimers do not provide a detectable excitation or emission peak in the unbound state. Upon binding with DNA or RNA however, the optical properties of the dimers change dramatically. In particular, the absorption curve shifts to a longer wavelength, and the dye now exhibits strong fluorescence. The dimers of benzthiazole derivatives, combined with nucleic acid

15 polymers, have an excitation maximum at about 510 nm and an emission maximum at about 530 nm, giving a Stokes shift of about 20 nm. The dimers of benzoxazole derivatives, combined with nucleic acid polymers, have an excitation maximum at about 490 nm and an emission maximum at about 510 nm, also giving a Stokes shift of about 20 nm (Table 1). It is worth noting that the argon ion laser, a high power source for fluorescence excitation, has

20 principle output lines at 514 nm and 488 nm, which coincide closely with the excitation maxima of the novel dimers.

Table 1: Absorption and Fluorescence Maxima of Representative Benzthiazole (Compound 1) and Benzoxazole (Compound 2) Dimers.

25

	Buffer ¹	Buffer + DNA ²	Methanol
Compound 1			
λ_A^3	475	513.2	507
λ_F^4	NF ⁵	533	NF
Compound 2			
λ_A	456	488	482
λ_F	NF	509	NF

30

¹10 mM Tris, 2 M NaCl, 1 mM EDTA: pH 7.4

²Between 15 and 35 mg/ml calf thymus DNA in the same buffer.

³ λ_A - wavelength of absorption maximum

⁴ λ_F - wavelength of fluorescence maximum

⁵NF - not sufficiently fluorescent for accurate determination

35


As is well known for cyanine dyes, [Griffiths, COLOUR AND CONSTITUTION OF ORGANIC MOLECULES, pp. 241 Academic Press (1976)], increasing the length of the polymethine bridge between the heterocyclic terminal groups results in a shift of the absorption spectrum to longer wavelengths.

5 The fluorescence of the dimers bound to DNA or RNA is enhanced typically about 1000 fold, sometimes as much as 5000 fold, depending on the amount of nucleic acid present in the sample. (See, e.g., Figure 4). This significant increase in fluorescence intensity eliminates the problem of background fluorescence due to unbound dye. The fluorescence intensity of the nucleic acid-dimer complex is proportional to the amount of
10 nucleic acid in the sample (Example 6; Fig. 4).

Because the dimer compounds do not readily cross the cell membrane of a healthy cell, the detection of fluorescence in a sample of whole cells can be used as an indication of the viability of cells in the sample. Cell death or toxicity usually results in loss of cell
15 membrane integrity. Thus, the fluorescence of single cells is an indicator that the cell membrane of such cells is not functioning normally, i.e. the fluorescent cells are not viable cells (Example 7).

EXAMPLE 1: PREPARATION OF A REPRESENTATIVE DIMER OF A
20 BENZTHIAZOLE DERIVATIVE (Compound 1)

The following compound is prepared:




A mixture of 0.72 g of a 1'-(3'-iodopropyl)-3-methyl-thia-4'-cyanine iodide precursor (prepared according to methods known in the art e.g. Brooker, et al. J. AM. CHEM. SOC. 64, 199 (1942)), and 69 mg of N,N,N',N'-tetramethylpropanediamine in 5 mL of DMF is heated at 130°C for one hour. After the reaction mixture cools down to room temperature,
35 40 mL of MeOH is added and stored at -20°C overnight. The red solid is filtered and recrystallized from DMF/MeOH again to yield the pure product Compound 1.

EXAMPLE 2: PREPARATION OF A REPRESENTATIVE DIMER OF A
BENZOXAZOLE DERIVATIVE (Compound 2)

The following compound is prepared:

5

10



The appropriate benzoxazole derivative dimer precursors are prepared according to Brooker, et al. J. AM. CHEM. SOC. 64, 199 (1942) and is dimerized according to the procedure of Example 1.


15

EXAMPLE 3: PREPARATION OF A REPRESENTATIVE DIMER WITH INCREASED
ABSORPTION WAVELENGTH (Compound 3)

A dimer of the following compound is prepared:

20

25




The monomer precursor is prepared from 2-(2-acetanilidovinyl)-3-methyl-benzothiazolium tosylate according to Brooker, et al. J. AM. CHEM. SOC. 64, 199 (1942) and is dimerized according to the procedure of Example 1.

30

EXAMPLE 4: PREPARATION OF A REPRESENTATIVE DIMER CONNECTED AT THE 2 POSITION OF THE QUINOLINE INSTEAD OF THE 4 POSITION (Compound 4)


The following compound is prepared:



The precursor 1'-(3'-iodopropyl)-3-methylthio-2'-cyanine iodide is prepared according to the method of Brooker, et al., J. AM. CHEM. SOC. 64, 199 (1942) and dimerized as above.

EXAMPLE 5: PREPARATION OF A REPRESENTATIVE DIMER WITH AN UNSUBSTITUTED ALKYL BRIDGING GROUP (Compound 5)

The following compound is prepared:



The compound is prepared from bi-(1'-(4-methylquinolinium)-1,3-propane dibromide and 2 equivalents of 2-methylthio-3-methylbenzothiazolium p-toluenesulfonate according to the method of Brooker, et al., J. AM. CHEM. SOC. 64, 199 (1942). The dibromide is obtained by refluxing 4.5 g of lepidine and 3 g of 1,3-dibromopropane in 4 ml of DMF for 6 hours. The solution is cooled to room temperature and 150 ml of ether is added to force out the product.

EXAMPLE 6: DNA TITRATIONS OF REPRESENTATIVE COMPOUNDS

A benzthiazole derivative dimer or a benzoxazole derivative dimer is prepared according to

procedures described above. The dye concentration in buffer (10 mM Tris, 1 mM EDTA, 50 mM NaCl pH 7.4) is 1 μ M. DNA (Calf Thymus DNA, Sigma Chemical Co. Product D-1501) is diluted from a 250 μ g/ml stock solution (based on $A_{260\text{ nm}} = 1.0 = 50 \mu\text{g/ml}$).

Fluorescence measurements are carried out on a Millipore Cytofluor 2300 microtiter plate reader using excitation at 485 nm (bandpass 20 nm) and emission detection at 530 nm (bandpass 25 nm). Fluorescence intensity is plotted against DNA concentration (Fig. 4).

EXAMPLE 7: QUANTITATIVE FLUORIMETRIC DETERMINATION OF DEAD CELLS

Cell line:

P3x63Ag8.653 (IgG, non-secreting mouse myeloma) from a BALB/c mouse.

Medium for propagation: Dulbecco's modified Eagle's medium with 10% calf serum, 1% HEPES Buffer solution, 1% L-Glutamine, and 0.5% Gentamicin.


Procedure:

Allow the cells to propagate for 3 to 4 days. Wash the cells 2 times in phosphate buffered saline (PBS) and centrifuge at 700 rpm for 10 minutes. Resuspend in PBS. Count the cells by trypan blue exclusion using a hemocytometer. Determine viability and adjust the cell concentration to 1.2×10^6 cells/ml. Divide the cells into two populations. Kill one population, for example by heating to 60°C for 15 minutes. Readjust the cell concentration to 600,000 cells/ml. Aliquot a known numbers of cells into a 96-well microtiter plate. Add PBS to the wells so that the volume is 200 μ l. Add 100 μ l of 6 μ M of the dimeric dye to each sample well so that the final concentration of dye is 2 μ M. Read the fluorescence versus cell number on a fluorescence microtiter plate reader (for example, Millipore Cytofluor 2300) using a suitable combination of excitation and emission filters. For compounds 1 and 2 excitation at 485 nm and emission detection at 530 nm is suitable. The linear proportionality of fluorescence signal to number of dead cells may be used to quantitatively assess cell viability.

It is to be understood that, while the foregoing invention has been described in detail by way of illustration and example, numerous modifications, substitutions, and alterations are possible without departing from the spirit and scope of the invention as described in the following claims.

What is claimed is:

1. A compound of the formula:



10 where R^1 and R^2 , which may be the same or different, are alkyl groups having 1-6 carbons;

X is O, S, or $N-R^3$, where R^3 is H or an alkyl group having 1-6 carbons;

Z is O, S, or $N-R^4$, where R^4 is H or an alkyl group having 1-6 carbons;

15

n and s, which may be the same or different, = 0, 1, or 2;

Y is $HC=CH$; and

20

p, m, q, and r = 0 or 1, such that $p + m = 1$ and $q + r = 1$; and

where -BRIDGE- has the general formula:



where α , β , γ , and δ , which may be the same or different, are integers greater than 1 and less than 5;

30

I and II, which may be the same or different, = 0 or 1; and

A^1 , A^2 , and A^3 , which may be the same or different, are independently O; S; $(CH_2)_\mu$, where $\mu = 0$ or 1; $-(NR^5)-$ where R^5 is H or an alkyl group having 1-6 carbons; or $-(N^+R^6R^7)-$ where R^6 and R^7 , which may be the same or different, are independently

35

hydrogen or an alkyl group having 1-6 carbons.

2. A compound, as claimed in Claim 1, where X is S.

3. A compound, as claimed in Claim 2, where Z is S, n and s = 0, and R¹ and R² are methyl groups.

5

4. A compound, as claimed in Claim 1, where X is O.

5. A compound, as claimed in Claim 4, where Z is O, n and s = 0, and R¹ and R² are methyl groups.

10

6. A compound, as claimed in Claim 1, where X and Z, which may be the same or different, are O or S; n = 1 or 2; and R¹ and R² are alkyl groups having 1-2 carbons.

7. A compound, as claimed in Claim 1, where A¹ and A³, which may be the same or different, are independently O; S; -(NR⁵)- where R⁵ is H or an alkyl group having 1-2 carbons; or -(N⁺R⁶R⁷)- where R⁶ and R⁷, which may be the same or different, are independently hydrogen or an alkyl group having 1-2 carbons.

15

8. A compound, as claimed in Claim 1, where R¹ and R², which may be the same or different, are alkyl groups having 1-2 carbons;

20

X and Z, which may be the same or different are O or S;

n and s = 0;

25

in the BRIDGE formula

α , β , γ , and δ , which may be the same or different, are 2 or 3;

30

A¹, A², and A³, which may be the same or different, are (CH₂) _{μ} where μ = 0; -(NR⁵)- where R⁵ is H or an alkyl group having 1-2 carbons; or -(N⁺R⁶R⁷)- where R⁶ and R⁷, which may be the same or different, are independently hydrogen or an alkyl group having 1-2 carbons.

35

9. A compound, as claimed in Claim 1, where R¹ and R², which may be the same or

different, are alkyl groups having 1-2 carbons;

X and Z, which may be the same or different are O or S;


5 n and s = 1 or 2;

in the BRIDGE formula

10 α , β , γ , and δ , which may be the same or different, are 2 or 3;

A^1 , A^2 , and A^3 , which may be the same or different, are $(CH_2)_\mu$ where $\mu = 0$; -
 (NR^5) - where R^5 is H or an alkyl group having 1-2 carbons; or $-(N^+R^6R^7)$ - where R^6
 and R^7 , which may be the same or different, are independently hydrogen or an alkyl
 15 group having 1-2 carbons.

10. A compound comprising a nucleic acid polymer bound to a dye of the general formula:



where R^1 and R^2 , which may be the same or different, are alkyl groups having 1-6 carbons;

25

X is O, S, or $N-R^3$, where R^3 is H or an alkyl group having 1-6 carbons;

Z is O, S, or $N-R^4$, where R^4 is H or an alkyl group having 1-6 carbons;


30 n and s, which may be the same or different, = 0, 1, or 2;

Y is $HC=CH$; and

p, m, q, and r = 0 or 1, such that $p + m = 1$ and $q + r = 1$; and

35

where -BRIDGE- has the general formula:



where α , β , γ , and δ , which may be the same or different, are integers greater than 1 and less than 5;

I and II, which may be the same or different, = 0 or 1; and

A^1 , A^2 , and A^3 , which may be the same or different, are independently O; S; $(\text{CH}_2)_\mu$ where $\mu = 0$ or 1; $-(\text{NR}^5)-$ where R^5 is H or an alkyl group having 1-6 carbons; or $-(\text{N}^+\text{R}^6\text{R}^7)-$ where R^6 and R^7 , which may be the same or different, are independently hydrogen or an alkyl group having 1-6 carbons;

with enhanced fluorescence.

11. A compound, as claimed in Claim 10, where X is S.

12. A compound, as claimed in Claim 11, where Z is S, n and s = 0, and R^1 and R^2 are methyl groups.

13. A compound, as claimed in Claim 10, where X is O.

14. A compound, as claimed in Claim 13, where Z is O, n and s = 0, and R^1 and R^2 are methyl groups.

15. A compound, as claimed in Claim 10, where X and Z, which may be the same or different, are O or S; n = 1 or 2; and R^1 and R^2 are alkyl groups having 1-2 carbons.

16. A compound, as claimed in Claim 10, where R^1 and R^2 , which may be the same or different, are alkyl groups having 1-2 carbons;

X and Z, which may be the same or different are O or S;

n and s = 0;

in the BRIDGE formula

α , β , γ , and δ , which may be the same or different, are 2 or 3;

5

A^1 , A^2 , and A^3 , which may be the same or different, are $(CH_2)_\mu$ where $\mu = 0$; -
(NR⁵)- where R⁵ is H or an alkyl group having 1-2 carbons; or -(N⁺R⁶R⁷)- where R⁶
and R⁷, which may be the same or different, are independently hydrogen or an alkyl
group having 1-2 carbons.

10

17. A compound, as claimed in Claim 10, where R¹ and R², which may be the same or
different, are alkyl groups having 1-2 carbons;

X and Z, which may be the same or different are O or S;

15

n and s = 1 or 2;

in the BRIDGE formula

20

α , β , γ , and δ , which may be the same or different, are 2 or 3;

A^1 , A^2 , and A^3 , which may be the same or different, are $(CH_2)_\mu$ where $\mu = 0$; -
(NR⁵)- where R⁵ is H or an alkyl group having 1-2 carbons; or -(N⁺R⁶R⁷)- where R⁶
and R⁷, which may be the same or different, are independently hydrogen or an alkyl
group having 1-2 carbons.

25

18. A compound as claimed in Claim 10, where the nucleic acid polymer is DNA.

30 19. A compound as claimed in Claim 10, where the nucleic acid polymer is RNA.

20. A compound, as claimed in Claim 10, where the enhanced fluorescence results from
loss of cell membrane integrity.

35




FIGURE 1




Figure 2B




Figure 2A




Figure 3A




Figure 3B

SUBSTITUTE SHEET




FIGURE 4

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 92/07867

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 G01N33/48; C09B23/00;	C09B23/08; G01N33/52;	C09B23/06; G01N33/58 C09B23/04
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	G01N ; C09B	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	CHEMICAL ABSTRACTS, vol. 88, no. 6, 6 February 1978, Columbus, Ohio, US; abstract no. 38936q, 'Dyes, Fluorescent Whitening agents and Photosensitizers' page 57 ;column 1 ; see abstract & UKR. KHIM. ZH. vol. 43, no. 9, 1977, USSR pages 953 - 956 I.L. MUSHKALO; L.S. TUROVA '3,3'-Ethylenebis(benzothiazolium) salts and their biscyanine dyes' ---	1-3
A	EP,A,0 226 272 (BECTON, DICKINSON & CO.) 24 June 1987 see page 1 - page 4 & US,A,4 883 867 cited in the application ---	1-20
<div style="display: flex; justify-content: space-between;"> <div> <p>¹⁰ Special categories of cited documents : ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
05 JANUARY 1993		11. 01. 93
International Searching Authority		Signature of Authorized Officer
EUROPEAN PATENT OFFICE		KETTERER M.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	NUCLEIC ACIDS RESEARCH vol. 19, no. 2, 25 January 1991, ARLINGTON, VIRGINIA US pages 327 - 333 RYE; QUESADA; PECK; MATHIES; GLAZER 'High -sensitivity two-color detection of double-stranded DNA with a confocal fluorescence gel scanner using ethidium homodimer and thiazole orange' cited in the application see page 328, column 2 -----	1-20
A	US,A,4 304 908 (FRISHBERG ET. AL.) 8 December 1981 see column 2 - column 4 -----	1

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9207867
SA 65194

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 05/01/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0226272	24-06-87	JP-C- 1594638	27-12-90
		JP-B- 2019428	01-05-90
		JP-A- 62112062	23-05-87
		US-A- 4883867	28-11-89
		US-A- 4957870	18-09-90

US-A-4304908	08-12-81	DE-A- 3124394	29-04-82
		JP-A- 57029070	16-02-82
		US-A- 4391886	05-07-83

EPO FORM P0019

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82




FIGURE 1




Figure 2B




Figure 2A

SUBSTITUTE SHEET




Figure 3A

SUBSTITUTE SHEET




Figure 3B

SUBSTITUTE SHEET




FIGURE 4

